H.R. 2821, the FDA Modernization Act 3.0, passed the House on July 20, 2026.
H.R. 2821 — FDA Modernization Act 3.0
What it does
This bill directs the FDA to replace all references to 'animal tests' with 'nonclinical tests' in its drug approval regulations within one year, and makes this regulatory change effective immediately without the usual public comment period. The change allows pharmaceutical companies to use alternative testing methods (such as computer models, cell cultures, or organ-on-a-chip technology) instead of animal testing, potentially accelerating drug development and reducing animal use.
Quorum's transparency scan gave FDA Modernization Act 3.0 a high transparency warning.
What happens next
H.R. 2821 passed the House. It now moves to the other chamber.
Who is behind it
Filed by Buddy Carter. Cosponsored by Brian Fitzpatrick, Chris Smith, Claudia Tenney and Dan Crenshaw.